Journal article

Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy

David K Packham, Rory Wolfe, Anne T Reutens, Tomas Berl, Hiddo Lambers Heerspink, Richard Rohde, Sara Ivory, Julia Lewis, Itamar Raz, Thomas B Wiegmann, Juliana CN Chan, Dick de Zeeuw, Edmund J Lewis, Robert C Atkins

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | AMER SOC NEPHROLOGY | Published : 2012

Abstract

Sulodexide, a mixture of naturally occurring glycosaminoglycan polysaccharide components, has been reported to reduce albuminuria in patients with diabetes, but it is unknown whether it is renoprotective. This study reports the results from the randomized, double-blind, placebo-controlled, sulodexide macroalbuminuria (Sun-MACRO) trial, which evaluated the renoprotective effects of sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria (>900 mg/d) already receiving maximal therapy with angiotensin II receptor blockers. The primary end point was a composite of a doubling of baseline serum creatinine, development of ESRD, or serum creatinine ≥6.0 mg/dl. We pl..

View full abstract